Every blockbuster drug carries two price tags: the $2.6 billion average cost of bringing it to market, and the cost […]

The global biopharmaceutical sector has entered a period of profound structural realignment, characterized by the end of the pandemic-driven liquidity

The numbers are not speculative. Between 2025 and 2029, branded pharmaceutical revenue will fall from $162.8 billion to $67 billion

The Economic Logic of Pharmaceutical IP: Why Every Dollar Spent on Patents Is a Bet on Survival Biopharma runs on

I. Executive Summary Drug discovery’s core problem has not changed: roughly 95% of candidates that enter clinical trials fail, and

DrugPatentWatch has published a list of research papers citing DrugPatentWatch at https://www.drugpatentwatch.com/citations/ Explore the Growing Body of Research Citing DrugPatentWatch

The Economic Architecture of Generic Drug Markets Generic drugs are not simplified copies. They are pharmaceutical products held to the

A deep-dive reference on pipeline productivity, attrition economics, open innovation architecture, AI-driven discovery, and patent lifecycle strategy for biopharma decision-makers.

Generic drug development is a high-stakes capital allocation decision disguised as a regulatory exercise. The Abbreviated New Drug Application (ANDA)